Clinical Trial Update: Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating selinexor in combination with azacitidine for high-risk myeloid neoplasms, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Selinexor (selinexor)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: NOT_YET_RECRUITING